Dermata Therapeutics (DRMA) news
Recent news
Dermata Therapeutics - to launch first commercial product Tome foundational treatment on August 25, 2026 - SEC filing
AInvest Wire · Aug 11, 2026ImportantDermata Therapeutics soars 55% on patent issued in Japan
Dermata Therapeutics soars 55% on patent issued in Japan Dermata Therapeutics, a late-stage biotechnology company, experienced a surge in its stocks by 55% following the issuance of a patent in Japan for its DMT410 program [1]. The DMT410 program focuses on the treatment of hyperhidrosis, a…
AInvest Wire · Jan 5, 2024ImportantDermata Therapeutics shares surge 83% in premarket after patent issued in Japan
Dermata Therapeutics shares surge 83% in premarket after patent issued in Japan Dermata Therapeutics, a late-stage biotechnology company, saw its shares surge by 83% in pre-market trading on [date] after receiving a patent for its DMT410 program in Japan. The patent is for the treatment of…
AInvest Wire · Jan 5, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.